2026 ADA Guidelines Standards of Care in Diabetes: Pharmacological Management of Type 2 Diabetes Mellitus
VIOLET Study Summary: Real World Evaluation of Vildagliptin and Vildagliptin + Metformin in Type 2 Diabetes Patients (DRC 2025)
Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop.
Use of extracorporeal circulation (ECLS/ECMO) for cardiac and circulatory failure -A clinical practice Guideline Level 3.
Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial.
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
